
Erasca Inc (ERAS) Stock Forecast & Price Target
Erasca Inc (ERAS) Analyst Ratings
Bulls say
Erasca is poised for success with a focused RAS/MAPK pathway pipeline and promising clinical data for both ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor. The potential for multi-blockbuster opportunities and strong management execution are expected to drive continued growth for the company. With a growing confidence in ERAS-0015's potential as a best-in-class pan-RAS therapy, a 25% probability of success, and an increase in our price target to $15, we maintain a Buy rating on Erasca.
Bears say
Erasca is currently focusing on developing therapies for RAS/MAPK pathway-driven cancers, but their potential advantage of ON/OFF RAS suppression through their molecular glue mechanism and high cyclophilin A binding affinity is still in question. The primary concerns for their clinical translation include establishing proof of concept for their deep pathway suppression and their potential to show responses in patients with varying KRAS alleles, while management's prioritization of indications for early monotherapy and comparison to mutant selective KRAS inhibitors remains important for future success.
This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.
Erasca Inc (ERAS) Analyst Forecast & Price Prediction
Start investing in Erasca Inc (ERAS)
Order type
Buy in
Order amount
Est. shares
0 shares